Solid Biosciences Inc. announced positive initial data from its Phase 1/2 INSPIRE DUCHENNE trial for SGT-003, showing an average microdystrophin expression of 110% and significant reductions in muscle injury markers, with cash reserves estimated at $148.9 million as of December 31, 2024.